News | September 18, 2025
Novo Nordisk’s Wegovy delivered 16.6% weight loss
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Encouraging early detection and breaking the silence around men’s health
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Subscribe To Our Newsletter & Stay Updated
